CytomX Therapeutics (NASDAQ:CTMX) Price Target Raised to $17.00

CytomX Therapeutics (NASDAQ:CTMX) had its price target lifted by HC Wainwright from $10.00 to $17.00 in a research report sent to investors on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for CytomX Therapeutics’ Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.56) EPS and FY2027 earnings at ($0.65) EPS.

A number of other research analysts have also weighed in on the stock. Barclays raised their price target on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. JPMorgan Chase & Co. upgraded shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $7.00 to $12.00 in a research note on Monday. Guggenheim reissued a “buy” rating and set a $10.00 target price on shares of CytomX Therapeutics in a research report on Monday, March 9th. Piper Sandler boosted their target price on CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $12.00 target price on shares of CytomX Therapeutics in a report on Monday. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, CytomX Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $12.56.

CytomX Therapeutics Trading Down 19.3%

NASDAQ CTMX opened at $4.40 on Monday. The firm has a market capitalization of $748.84 million, a P/E ratio of -110.00 and a beta of 2.44. The business has a fifty day simple moving average of $5.27 and a 200 day simple moving average of $4.10. CytomX Therapeutics has a 12 month low of $0.40 and a 12 month high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%.The firm had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $7.33 million. As a group, sell-side analysts predict that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Institutional Trading of CytomX Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Orbimed Advisors LLC bought a new stake in CytomX Therapeutics in the second quarter worth about $19,208,000. Commodore Capital LP purchased a new position in CytomX Therapeutics in the second quarter valued at about $17,462,000. Perceptive Advisors LLC bought a new position in shares of CytomX Therapeutics during the 2nd quarter valued at approximately $15,876,000. Vivo Capital LLC bought a new position in shares of CytomX Therapeutics during the 2nd quarter valued at approximately $13,096,000. Finally, Franklin Resources Inc. purchased a new stake in shares of CytomX Therapeutics during the 2nd quarter worth approximately $13,096,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

Trending Headlines about CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Multiple analysts raised price targets or upgraded the stock — Guggenheim raised its target to $15 and put a Buy on CTMX, Wedbush raised its target to $11 with an Outperform, and JPMorgan issued an upgrade — these notes signal continued institutional interest and provide upside conviction for the shares. Benzinga JPMorgan Upgrade
• Positive Sentiment: Clinical catalyst: strong Phase I Varseta‑M data in metastatic colorectal cancer previously triggered a rally and underpins investor optimism about the pipeline’s upside. Zacks
• Neutral Sentiment: Company posted its Q4 results presentation (useful for diligence), providing the latest formal disclosures on operations and pipeline progress. Investors should review the deck for cash runway details and program timelines. Q4 Presentation
• Negative Sentiment: Dilutive equity financing: CytomX priced a $250M offering at $5.30/share (≈46M shares plus pre‑funded warrants). The sale increases share count materially and is the primary near‑term headwind pressuring the stock. Offering Filing
• Negative Sentiment: HC Wainwright lowered near‑term EPS forecasts substantially (Q1–Q4 2026 and FY2026 cuts) even while maintaining a Buy and a $17 target; the reduced estimates highlight expected near‑term cash burn and push downside to short‑term earnings expectations. Analyst Note
• Negative Sentiment: Recent quarter missed consensus on EPS and revenue (reported March 16), underscoring why the company sought additional capital and why near‑term profitability looks distant. Earnings Coverage

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.